• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease

byJames RoebkerandDayton McMillan
January 25, 2019
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. During an 80-week trial period of patient’s with early Parkinson’s disease (PD), there was no difference in the severity of symptoms between patients treated with levodopa-carbidopa for all 80 weeks (early-start group) versus those treated with levodopa-carbidopa for the second 40 weeks (delayed-start group).

2. There was no significant difference between the rates of dyskinesia and levodopa-related motor fluctuations at 80 weeks between the early-start and delayed-start groups.

Evidence Rating Level: 1 (Excellent)   

Study Rundown: Though the ELLDOPA trial demonstrated that patients with early PD received clinical benefit from levodopa two weeks after the medication was stopped, it is unclear whether this due to disease-modifying activity or prolonged symptomatic relief. To differentiate between disease-modifying and symptomatic effects, the Levodopa in Early Parkinson’s Disease (LEAP) trial randomized patients to levodopa-carbidopa for 80 weeks (early-start group) or placebo for 40 weeks followed by levodopa-carbidopa for 40 weeks (delayed-start group). The authors found no significant difference in the primary outcome – change from baseline to week 80 in the Unified Parkinson’s Disease Rating Scale (UPDRS) – at the end of the trial period. The primary outcome was further supported by a noninferiority analysis of disease progression between the groups in the second phase of the trial. Among secondary outcomes, there was no significant difference in disability, cognitive impairment, depression, or quality of life. The results of this trial suggest that levodopa does not have a disease-modifying effect on the progression of PD.

This trial was designed in two phases to differentiate between a prolonged effect on PD symptoms and a disease-modifying effect, and additionally included a prespecified progression analysis to further support the findings. Limitations include the absence confirmatory neuroimaging, given the high rate of clinical misdiagnosis in PD. Furthermore, the author’s used an intermediate dose of levodopa-carbidopa, and thus the results may differ with a higher or lower dose.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Deferiprone is associated with worsening Parkinson’s symptoms in patients naïve to dopaminergic drugs

ENT-01 reduces rates of constipation in patients with Parkinson’s disease

Prasinezumab therapy does not affect Parkinson’s Disease progression

Relevant Reading: Levodopa and the progression of Parkinson’s Disease

In-Depth [randomized controlled trial]: Patients diagnosed with PD (n=445) were randomized to treatment with levodopa (100mg three times daily) and carbidopa (25mg three times daily) for 80 weeks (early-start group; n=222) or with placebo for 40 weeks followed by levodopa-carbidopa for 40 weeks (delayed-start group; n=223). The primary outcome was the difference between the early- and delayed-start groups in mean change from baseline to week 80 in the total score on the UPDRS. Secondary outcomes at 80 weeks included disability assessed by the Academic Medical Center Linear Disability Score (ALDS), cognitive impairment assessed by the Mini-Mental State Examination (MMSE), depression assessed by the Beck Depression Inventory II (BDI-II), and quality of life assessed by the Parkinson’s Disease Questionnaire-39 (PDQ-39).

Among the 445 patients randomized, 207 patients in the early-start group and 210 patients in the delayed-start group completed the 80-week trial. The mean change in UPDRS in the early-start group was -1.0±13.1 points vs. -2.0±13.0 points in the delayed-start group (between-group difference 1.0; 95% confidence interval [CI], -1.5 to 3.5; P=0.44). The change in UPDRS from baseline to week 40 was -3.1±10.2 in the early-start group vs. 2.0±12.3 in the delayed-start group (difference, -5.1 points; 95% CI, -7.2 to -2.9). Between weeks 4 and 40, the change in UPDRS points per week (measure of progression) was 0.04±0.23 in the early-start group vs. 0.06±0.34 in the delayed-start group (difference, -0.02; 95% CI, -0.07 to 0.03). The rate of change between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two-sided 90% CI, 0.03 to 0.10), which did not meet non-inferiority of early to delayed receipt of levodopa. There was no significant difference between the two groups in ALDS, MMSE, BDI-II, and PDQ-39 scores. The early-start group had a higher incidence of nausea in the first 40 weeks of the trial (23.0% vs 14.3%; P=0.02). At 80 weeks, there was no significant difference in motor complications between the groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

 

Tags: carbidopalevodopaParkinson’s Disease
Previous Post

Quick Take: Association of Rates of Smoking During Pregnancy With Corporate Tobacco Sales Poicies

Next Post

Dapagliflozin associated with reduced hospitalization rate for heart failure

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deferiprone is associated with worsening Parkinson’s symptoms in patients naïve to dopaminergic drugs

December 7, 2022
Dual-energy CT may improve detection of acute small bowel ischemia
Chronic Disease

ENT-01 reduces rates of constipation in patients with Parkinson’s disease

November 21, 2022
Chronic Disease

Prasinezumab therapy does not affect Parkinson’s Disease progression

August 12, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Adjuvant treatment with catechol-O-methyltransferase inhibitors inferior to monoamine oxidase type B inhibitors or dopamine agonists in patients with Parkinson disease uncontrolled by levodopa therapy

December 29, 2021
Next Post
Food environment associated with gestational diabetes

Dapagliflozin associated with reduced hospitalization rate for heart failure

Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Quick Take: Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

#VisualAbstract: Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

#VisualAbstract: Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options